The Food and Drug Administration approved a vaccine from Pfizer that protects infants from respiratory syncytial virus, the leading cause of hospitalization among babies in the U.S. The company's ...

The FDA approved Pfizer's maternal vaccine to protect newborns from RSV. Courtesy Pfizer Still, the vaccine, given from 32 to 36 weeks of gestational age, does not provide long-term protection.

The FDA approved the first vaccine for pregnant women to prevent RSV in infants. The vaccine would allow babies to be born ...

Updated COVID-19 vaccines from Moderna and Pfizer/BioNTech approved by FDA, effective against dominant EG.5 strain in the US.

The Food and Drug Administration approved the first-ever vaccine for respiratory syncytial virus, which uses breakthrough ...

US regulators approved updated versions of the COVID-19 vaccines made by Pfizer Inc. and Moderna Inc. Monday as ...

RSV vaccines are available for individuals 60 and older now. New COVID-19 vaccines targeting current variant could be ...

The new RSV vaccine is currently available to seniors over the age of 60. Just four states require qualified people to obtain ...

Public health officials, as well as drugmakers, are trying to raise awareness of RSV among older adults at risk, and convince them to get an additional respiratory shot alongside those for COVID and ...

Bocchini said it’s safe for children to receive the COVID shot together with their flu vaccine and, if eligible, the new RSV ...

The surge in RSV, a common respiratory virus, moving across the southeastern United States could be seen in Madison County.

The U.S. approved updated COVID-19 vaccines Monday, hoping to rev up protection against the latest coronavirus strains and ...